US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria: Paris Monday, November 18, 2024, 11:00 Hrs [IST] The US Food and Drug Admin ...
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental Biologics License ...
Paris: Sanofi and Regeneron has announced that the US Food and Drug Administration (FDA) has accepted for review the ...
The resubmitted sBLA will include results from Study C, which evaluated biologic-naive patients with uncontrolled CSU on antihistamines.
The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.
The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...
Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a ...
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity M ...
French drug major Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the U.S. Food and Drug Administration ...
The companies did not provide detailed data for Tezspire, however, and William Blair’s Matt Phipps said in a note he does not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback